Would raising the total cholesterol diagnostic cut-off from 7.5 mmol/L to 9.3 mmol/L improve detection rate of patients with monogenic familial hypercholesterolaemia?

M. Futema a, M. Kumari b, C. Boustred c, M. Kivimaki d, S.E. Humphries a, *

a Centre for Cardiovascular Genetics, British Heart Foundation Laboratories, Institute of Cardiovascular Science, The Rayne Building, University College London, London, WC1E 6JF, UK
b University of Essex, Wivenhoe Park, Colchester, Essex, CO4 3SQ, UK
c NE Thames Regional Genetics Service, Great Ormond Street Hospital for Children, London, UK
d Department of Epidemiology & Public Health, UCL Institute of Epidemiology & Health Care, University College London, London, UK

ARTICLE INFO
Article history:
Received 19 December 2014
Received in revised form
14 January 2015
Accepted 15 January 2015
Available online 28 January 2015

Keywords:
Familial hypercholesterolaemia
Diagnosis
LDLR
APOB
Cholesterol

A B S T R A C T
A previous report suggested that 88% of individuals in the general population with total cholesterol (TC) > 9.3 mmol/L have familial hypercholesterolaemia (FH). We tested this hypothesis in a cohort of 4896 UK civil servants, mean (SD) age 44 (±6) years, using next generation sequencing to achieve a comprehensive genetic diagnosis. 25 (0.5%) participants (mean age 49.2 years) had baseline TC > 9.3 mmol/L, and overall we found an FH-causing mutation in the LDLR gene in seven (28%) subjects. The detection rate increased to 39% by excluding eight participants with triglyceride levels over 2.3 mmol/L, and reached 75% in those with TC > 10.4 mmol/L. By extrapolation, the detection rate would be ~25% by including all participants with TC > 8.6 mmol/L (2.5 standard deviations from the mean). Based on the 1/500 FH frequency, 30% of all FH-cases in this cohort would be missed using the 9.3 mmol/L cut-off. Given that an overall detection rate of 25% is considered economically acceptable, these data suggest that a diagnostic TC cut-off of 8.6 mmol/L, rather than 9.3 mmol/L would be clinically useful for FH in the general population.

© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Familial Hypercholesterolaemia (FH) in its classical form is an autosomal dominant disorder, characterised by increased plasma levels of low-density-lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) from birth and premature cardiovascular events. FH affects about 1/200 [1] to 1/500 [2] individuals of the Caucasian population, with an estimated 1.8 to 4.5 million people affected in Europe [3], and between 120,000–240,000 people in the UK with heterozygous FH, of whom at least 75% are undiagnosed [4]. The clinical diagnosis in the UK is based on the criteria of elevated TC and LDL-C levels (>7.5 mmol/L and >4.9 mmol/L, respectively), and family history of early coronary heart disease (CHD) and/or elevated cholesterol levels, when patients are given a diagnosis of possible FH (PFH), and the presence of clinical features such as tendon xanthomas, when patients are given a diagnosis of definite FH (DFH) [2]. In Europe, a scoring system developed in Holland [3] is more widely used.

Recently, the need for implementation of universal or targeted screening for FH to tackle the disease underdiagnosis and undertreatment has been highlighted [1,3]. Early identification of at-risk individuals allows changes in lifestyle including dietary intervention, and drug treatment, which have been shown to reduce coronary atherosclerosis and to improve life expectancy [5–7]. Cascade testing using the family mutation to identify carrier relatives unambiguously is a cost-effective method of finding additional FH patients, and has been used extensively in other countries in Europe, most notably in Holland, for the last five years [8]. Improved identification of FH cases has recently been included in the new UK Department of Health Cardiovascular Outcomes Strategy (https://www.gov.uk/government/publications/improving-cardiovascular-disease-outcomes-strategy), and a newly issued set of NICE Quality Standards (QS41) underline the existing guidance for the diagnosis, cascade screening and

* Corresponding author.
E-mail address: steve.humphries@ucl.ac.uk (S.E. Humphries).

http://dx.doi.org/10.1016/j.atherosclerosis.2015.01.028
0021-9150/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
management of FH in England [9]. Based on the Simon Broome criteria, individuals with TC > 7.5 mmol/L and/or LDL-C > 4.9 mmol/L should be assessed for a clinical diagnosis of FH. However, there is concern that this proposed cut-off is too low and will result in many false positive diagnoses and a high workload for lipid clinics.

2. Hypothesis and methods

A previous study [10] suggested that 88% of the general population in the US (age > 40 years) with TC > 9.3 mmol/L (and/or LDL-C > 6.8 mmol/L) and normal triglycerides (TG < 2.3 mmol/L) are expected to have an FH-causing mutation. We aimed to test this hypothesis using targeted next generation sequencing (NGS) (Illumina TruSeq Custom Amplicon and MiSeq Illumina sequencer) methods for genetic diagnosis of FH [11] in the Whitehall II prospective cohort study (WHII) of British civil servants [12]. The criteria of our standard variant calling pipeline were: coverage ≥ 30×, minimum of five reads for an altered allele, Phred quality ≥ 20, and a strand bias filter. To ensure that variants were not missed a sensitive pipeline was used (coverage ≥ 15×, minimum of two reads for an altered allele, Phred quality ≥ zero, no strand bias filter). Copy number variants (CNVs) were called using the ExomeDepth package [13]. All variants were confirmed by Sanger sequencing or for CNVs by MLPA [14]. The polygenic cause of

![Fig. 1. The relationship of TC and FH mutation detection rate. A. TC distribution in WHII (n = 4896). Red lines indicate the proposed TC cut-offs (7.5 mmol/L, 8.6 mmol/L and 9.3 mmol/L) and the proportion of the cohort above those cut-offs. Green arrow indicates the TC mean (5.9 mmol/L). One, two and three standard deviations (SD) to the right of the mean are also marked. B. Percentage of adults with FH predicted by Williams et al. in comparison to FH mutation carriers in WHII and Oxford FH [18]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](image-url)
hypercholesterolaemia in the WHII cohort was also assessed using a 6-SNP genetic risk score [15,16].

3. Results

In the cohort of 4896 WHII participants recruited in 1985–99 (baseline characteristics shown in the Supplement Table S1), for whom DNA samples were available, we identified 25 subjects (0.5%) with a baseline TC > 9.3 mmol/L (TC distribution shown in Fig. 1A). This group was sequenced for mutations in four FH genes (LDLR, APOB, PCSK9 and LDLRAP1) and genotyped for six LDL-C-associated SNPs (rs629301 in CELSR2, rs1367171 in APOB, rs6544713 in ABCG5/8, rs6511720 in LDLR, and rs429358 and rs7412 in APOE). Causality of identified variants was thoroughly assessed considering previously published studies and in silico tools [17].

Considering the conservative 1/500 frequency of FH, we would expect 10 FH individuals in this cohort. An LDLR mutation, including one CNV (Supplement Fig. S1) was found in 28% (n = 7) of sequenced individuals (Table 1), which accounted for 70% of the estimated FH in WHII. The sensitive variant-calling pipeline did not detect any additional mutations. The APOB p.R3527Q mutation, which is known to account for about 5% of FH mutations in the UK [18] was not found. However, our previous analysis of the WHII cohort using the Metabochip [19] identified two carriers of the p.R3527Q mutation. FH patients affected by the APOB mutation are known to have lower TC/LDL-C than those with a defective LDL-receptor [18,20]. In this case the two p.R3527Q mutation carriers had TC of 9.3 mmol/L and 5.9 mmol/L and therefore they were missed by the >9.3 mmol/L cholesterol cut-off criteria.

Polygenic hypercholesterolaemia is thought to account for the majority of clinically diagnosed FH cases where no mutation can be found [15,21]. Out of the 18 mutation negative individuals eight had a 6-SNP LDL-C genetic risk score above the top quartile of the score distribution, and 16 had a score in the top three quartiles of the distribution, and 16 had a score in the top three quartiles of the distribution, and 16 had a score in the top three quartiles of the distribution, and 16 had a score in the top three quartiles of the distribution. Of the unexplained two individuals, one had high TG levels (2.75 mmol/L), which could suggest a diagnosis of familial polygenic (Table 2), which confirms our previous findings that the FH mutation detection rate correlates positively with pre-treatment TC and negatively with pre-treatment TG [18].

We repeated the analysis after excluding individuals with TG > 2.3 mmol/L (n = 8, all were mutation negative), which led to an increase in the percentage of subjects with TC > 9.3 mmol/L who were FH-mutation carriers from 28% to 39% (Fig. 1B). We then compared these results with a previously published cohort of FH patients from an Oxford lipid clinic, who had been identified using the standard Simon Broome criteria of TC > 7.5 mmol/L plus having a family history of high cholesterol or premature CHD [2]. In this sample of DFH and PFH patients overall the mutation the percentage of FH mutation carriers was 37% and among individuals with TC > 9.3 mmol/L was 58%, which was significantly higher than in the WHII subjects (p = 0.01 (χ²2)) (Fig. 1B), reinforcing the utility of family history information in identifying mutation carriers.

4. Discussion

Based on the classical frequency of heterozygous FH of 1/500 we expected to find 10 mutation carriers in the ~5000 subjects included here, and successfully identified seven i.e. 70% of predicted. However, if the true frequency of FH in the UK is similar to the 1/250 reported in Denmark [1], with this estimate supported by the frequency of 1/217 of LDLR mutation carriers observed by exome sequencing [22], our overall detection rate would be only 35% (i.e. 7 of the 20 expected in the 5000 subjects examined). While it is possible that some mutation carriers were missed for technical reasons in the next generation sequencing or bioinformatics methods used, reducing the stringency of calling did not identify any additional variants, which were confirmed by Sanger sequencing. It is most likely that some FH patients carrying “mild” mutations (or with few common LDL-C raising variants i.e. a low 6-SNP score) would not have been included in the selected 25 subjects, as clearly shown by the exclusion of the two previously identified APOB p.R3527Q carriers. For example, in the study of 101 mutation-positive FH patients from the Oxford lipid clinic [18] mean TC in LDLR mutation carriers was 9.81 (±1.52) mmol/L, and in the APOB p.R3527Q carriers was 9.12 (±0.85) mmol/L. In the Oxford group, only 58% of mutation carriers would have been detected using the 9.3 mmol/L TC threshold proposed by Williams et al. [9].

The reason for the significantly lower detection rate at a TC cut-off of 9.3 mmol/L in WHII compared to that predicted by Williams et al. (28% vs 88%) is unclear, but will be influenced by the distribution of TC levels in the two samples (Utah mean TC = 5.3 ± 1.0 mmol/L vs. 5.9 ± 1.1 mmol/L in WHII), as well as

### Table 1

<table>
<thead>
<tr>
<th>Number of carriers</th>
<th>DNA change</th>
<th>Protein change</th>
<th>Baseline total cholesterol (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>c.266G &gt; A</td>
<td>p.(Cys89Tyr)</td>
<td>11.6</td>
</tr>
<tr>
<td>1</td>
<td>c.1048C &gt; T</td>
<td>p.(Arg350?)</td>
<td>12.4</td>
</tr>
<tr>
<td>1</td>
<td>c.1135T &gt; C</td>
<td>p.(Cys379Arg)</td>
<td>10.2</td>
</tr>
<tr>
<td>1</td>
<td>c.1238C &gt; T</td>
<td>p.(Thr413Met)</td>
<td>9.8</td>
</tr>
<tr>
<td>1</td>
<td>c.1444G &gt; A</td>
<td>p.(Asp482Asn)</td>
<td>9.4</td>
</tr>
<tr>
<td>1</td>
<td>c.1845 + 11C &gt; G</td>
<td>Splicing changed</td>
<td>11.2</td>
</tr>
<tr>
<td>1</td>
<td>c.68-7_940+7del</td>
<td>Deletion of exons</td>
<td>11.9</td>
</tr>
</tbody>
</table>

* Sequence number using LDLR transcript: NM_000527.4 (numbered from ‘A’ (no.1) in the ‘ATG’ codon). Sequence density plots were used to determine the presence of insertions and deletions and are presented in Supplementary material.
different underlying genetic and environmental factors of the two
groups. While we do not have data on the number of FH-causing
mutation carriers that would have been detected if screening had
been carried out at lower TC levels, extrapolation of the detection
rate data in Fig. 1 in the WHII sample where subjects with
gTG > 2.3 mmol/L were excluded, suggests that roughly 15% of
subjects with TG > 7.5 mmol/L would be carriers. If an overall
detection rate of 25% were considered economically acceptable
(close to the reported detection rate in BRACAI/2 in women with a
family history of breast cancer [23] then a TC cut-off of >8.6 mmol/L
in 50 year old participants may be clinically useful. Although in this
study we were unable to assess the percentage of FH mutation
carriers in individuals with TC in the range of 8.6–9.3 mmol/L, we
estimated that using a cut-off of 2.5 standard deviations from the
TC mean of a screened population would achieve a ~25% mutation
detection rate (Fig. 1A). Based on the WHII cohort, lowering the TC
cut-off to 8.6 mmol/L would increase the number of individuals
who need the FH genetic test by three times (from 0.5% to 1.7% of
the population), and by 10 times if the Simon Broome FH cut-off
was used.

Taken together, in a general population opportunistic screening
situation, these findings may help to select individuals for an FH
DNA test using the TC measurement. However, the additional
assessment of family history and TG levels in potentially affected
individuals will significantly improve the detection rate.

5. Limitations

Although we have previously demonstrated that NGS methods
for the detection of FH mutations are robust and more sensitive
than standard methods, including Sanger sequencing [24], we
recognise that Sanger re-sequencing of the FH genes in our cohort
could provide additional evidence that no mutations were missed.
The 8.6 mmol/L TC cut-off was identified using an extrapolation
approach, which is subject to uncertainty. Lack of sequencing data
for individuals with TC ≤ 9.3 mmol/L prevents the analysis of the
true sensitivity/specificity of the FH diagnosis in these individuals.

Acknowledgements

SEH holds a Chair funded by the British Heart Foundation, and
SEH and MF are supported by the BHF (PG08/008) and by the Na-
tional Institute for Health Research University College London
Hospitals Biomedical Research Centre (BRC68). The WHII study is
supported by grants from the Medical Research Council (K013351;
ID85374), British Heart Foundation (RG/07/008/23674), Stroke As-
nociation, National Heart Lung and Blood Institute (HL036310),
National Institute on Aging (SR01AG13196) Agency for Health Care
Policy Research (HS06516), and the John D. and Catherine T. Mac-
Arthur Foundation Research Networks on Successful Midlife
Development and Socio-economic Status and Health. We thank
Prof Nick Lench and Dr Emma Ashton for their assistance in using
of sequencing equipment in the Regional Genetics Laboratory Great
Ormond Street Hospital for Children.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.atherosclerosis.2015.01.028.

References

[1] M. Benn, G.F. Watts, A. Tybjaerg-Hansen, B.G. Nordestgaard, Familial hyper-
cholesterolaemia in the Danish general population: prevalence, coronary artery
disease, and cholesterol-lowering medication, J. Clin. Endocrinol. Metab. 97
(Nov 2012) 3956.
natural history, and treatment of familial hypercholesterolaemia, Athero-
sclerosis 168 (May, 2003) 1.
[3] B.G. Nordestgaard, et al., Familial hypercholesterolaemia is undiagnosed and
undertreated in the general population: guidance for clinicians to prevent
(coronary heart disease: consensus statement of the European Atherosclerosis
undiagnosed of familial hypercholesterolaemia in routine practice: pro-
treated patients with heterozygous familial hypercholesterolaemia: a pro-
e3228.
cost-effectiveness analysis of cascade screening for familial hyper-
cholesterolaemia using alternative diagnostic and identification strategies.
Heart 97, Jul (2011) 1175.
J.J. Kastelein, Review of first 5 years of screening for familial hyper-
cholesterolaemia in the Netherlands, Lancet 357 (Jan 29, 2001) 165.
hypercholesterolaemia: a pressing issue for European health care, Athero-
sclerosis 231 (Dec, 2013) 223.
using new practical criteria validated by molecular genetics, Am. J. Cardiol. 72
P. Giles, R. Aylng, K. Haralambos, S. Whately, I. McDowell, M. Williams, The
impact of routine next generation sequencing testing for familial hyper-
cholesterolaemia — 5 months service experience, Atherosclerosis 236 (2014)
e763.
Whithead II study, Lancet 337 (Jun 8, 1991) 1387.
experiments and implications for copy number variant calling, Bioinformatics
screen for deletions and duplications of the LDLR gene in patients with fa-
distinguish patients with polygenic and monogenic familial hyper-
cholesterolaemia: a case-control study, Lancet 381 (Apr 13, 2013) 1293.
[16] M. Futema, et al., Refinement of variant selection for the LDL cholesterol ge-
netic risk score in the diagnosis of the polygenic form of clinical familial hy-
percholesterolaemia and replication in samples from 6 countries, Clin. Chem.
[17] C. Usflo, et al., Low-density lipoprotein receptor gene familial hypercholes-
Genet. 76 (Sep, 2012) 387.
[18] M. Futema, et al., Analysis of the frequency and spectrum of mutations rec-
ognised to cause familial hypercholesterolaemia in routine clinical practice in
a UK specialist hospital lipid clinic, Atherosclerosis 229 (1) (2013 Jul)
161–168.
[20] S.E. Humphries, et al., Genetic causes of familial hypercholesterolaemia in
patients in the UK: relation to plasma lipid levels and coronary heart disease
[21] P.J. Talmud, M. Futema, S.E. Humphries, The genetic architecture of the fa-
milial hyperlipidaemia syndromes: rare mutations and common variants in
[22] M. Futema, et al., Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for
myocardial infarction, Nature (2014 Dec 10), http://dx.doi.org/10.1038/na-
ture13917 (Epub ahead of print).
[23] D.G. Evans, et al., Probability of BRCA1/2 mutation varies with ovarian his-
tology: results from screening 442 ovarian cancer families, Clin. Genet. 73
(Apr, 2008) 338.
exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia,